Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M

Loading...
Loading...
  • Pyxis Oncology Inc PYXS agreed to acquire Apexigen Inc APGN in an all-stock transaction for an implied value of $0.64 per Apexigen share
  • Apexigen went public in a blank-check deal just last summer.
  • For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million.
  • In February, Apexigen announced evaluating alternatives and reduced its workforce by 55%.
  • "This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation by adding humanized antibody generation to our Flexible Antibody Conjugation Technology (FACT) ADC toolkit acquired from Pfizer," said Lara S. Sullivan, President & CEO of Pyxis Oncology.
  • Pyxis Oncology ended Q1 FY23 with approximately $150.8 million in cash.
  • Effective June 15, 2023, Jay Feingold will step down as Chief Medical Officer to pursue other opportunities. He will remain an advisor to Pyxis Oncology until a successor is named.
  • Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders.
  • The transaction is anticipated to close by mid-2023.
  • The combined company will trade on Nasdaq under the ticker symbol PYXS. The existing Pyxis Oncology leadership team will continue, including Lara S. Sullivan as President & CEO, Pamela Connealy as CFO & COO, and Jan Pinkas as Chief Scientific Officer.
  • In 2021, Pyxis Oncology entered into a worldwide license agreement with Pfizer Inc PFE for two antibody-drug conjugate (ADC) candidates and a license to Pfizer's ADC technology platform.
  • Price Action: APGN shares are up 39.5% at $0.56, and PYXS shares are down 8.92% at $3.40 on the last check Wednesday.
Loading...
Loading...
Posted In: BiotechM&ANewsPenny StocksHealth CareMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...